Abu dhabi: Abu Dhabi Biobank, a strategic initiative between the Department of Health Abu Dhabi and M42, has entered a collaboration with AstraZeneca, a global science-led biopharmaceutical leader, to advance the fields of precision medicine and the translation of clinical research into clinical practices. The partnership aims to blend Abu Dhabi Biobank's biobanking and genomic infrastructure with AstraZeneca's expertise in several therapeutic areas, including cardiovascular, renal, metabolic, respiratory, immunology, and oncology.
According to Emirates News Agency, the collaboration seeks to translate complex biological insights into practical healthcare solutions capable of transforming lives. Albarah ElKhani, Chief Operating Officer of Integrated Health Solutions at M42, emphasized that the collaboration is more than a partnership, describing it as a shared vision to shape the future of medicine. By integrating Abu Dhabi Biobank's population insights with AstraZeneca's scientific prowess, both parties aim to redefine the understanding, prevention, and treatment of diseases, particularly within the Middle Eastern population.
Abu Dhabi Biobank and AstraZeneca plan to collaborate across several strategic pillars, utilizing the Biobank's extensive repository of biospecimens, datasets, and research infrastructure. The partnership will explore clinical development, precision medicine, and real-world evidence generation to advance biomarker discovery, pharmacogenomics, and patient stratification. Additionally, it will support health economics, regulatory science, and emerging fields such as digital health and AI, contributing to data-driven healthcare systems.
Sameh ElFangary, Country President for Gulf and Pakistan at AstraZeneca, highlighted the importance of reflecting the diversity of global populations in precision medicine. Through the partnership, world-class science will be combined with local data to facilitate the early identification of at-risk patients, especially those with rare and difficult-to-diagnose diseases, and to shape more personalized care pathways for the future. This collaboration is seen as a significant step toward advancing equitable and data-driven healthcare for patients across the region and beyond.
This partnership marks a key milestone in Abu Dhabi's ambition to become a global hub for biomedical research and life sciences innovation. By leveraging longitudinal cohort data and population-specific insights, it aims to accelerate the transition from research to regulatory approval and clinical application. The collaboration will harness Abu Dhabi Biobank's high-quality biospecimens, datasets, and biobanking capabilities, alongside AstraZeneca's expertise in translational and clinical research, to accelerate the development of locally relevant and globally significant medical insights. This initiative sets a new standard for how collaborative science can convert data into improved health outcomes.